Evidence map›Paper›PMID 37884953›Full record

ArticleBMC pulmonary medicine2023

Searching for airways biomarkers useful to identify progressive pulmonary fibrosis.

Piera Soccio, Giorgia Moriondo, Giulia Scioscia, Valentina Leo, Pasquale Tondo, Luciana Salerno, Paolo Palange, Maria Pia Foschino Barbaro, Donato Lacedonia

Open access · goldAbstract read
In one paragraph

Article in BMC pulmonary medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. The dual promise of extracellular vesicles in lung diseases: towards reliable biomarkers and drug delivery vectors.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Piera Soccio *Department of Medical and Surgical Sciences, University of Foggia, Viale Luigi Pinto, 1, Foggia, 71122, Italy. piera.soccio@unifg.it.
Giorgia Moriondo *Department of Medical and Surgical Sciences, University of Foggia, Viale Luigi Pinto, 1, Foggia, 71122, Italy.
Giulia SciosciaDepartment of Medical and Surgical Sciences, University of Foggia, Viale Luigi Pinto, 1, Foggia, 71122, Italy.
Valentina LeoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Viale Università, 37, Rome, 00185, Italy.
Pasquale TondoDepartment of Medical and Surgical Sciences, University of Foggia, Viale Luigi Pinto, 1, Foggia, 71122, Italy.
Luciana SalernoDepartment of Medical and Surgical Sciences, University of Foggia, Viale Luigi Pinto, 1, Foggia, 71122, Italy.
Paolo PalangeDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Viale Università, 37, Rome, 00185, Italy.
Maria Pia Foschino BarbaroDepartment of Medical and Surgical Sciences, University of Foggia, Viale Luigi Pinto, 1, Foggia, 71122, Italy.
Donato LacedoniaDepartment of Medical and Surgical Sciences, University of Foggia, Viale Luigi Pinto, 1, Foggia, 71122, Italy.
University of Foggia · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIdiopathic pulmonary fibrosis (IPF) is a chronic and progressive disorder with unknown etiology. To date, the identification of new diagnostic, prognostic and progression biomarkers of IPF turns out to be necessary. MicroRNA (miRNA) are small non-coding RNAs which negatively regulate gene expression at the post-transcriptional level in several biological and pathological processes. An aberrant regulation of gene expression by miRNA is often associated with various diseases, including IPF. As result, miRNAs have emerged as potential biomarkers with relevance to pulmonary fibrosis. Several reports suggested that miRNAs are secreted as microvesicles or exosome, and hance they are stable and can be readily detected in the circulation. In the contest of miRNAs as circulating biomarkers, different studies show their role in various types of interstitial lung diseases and suggest that these small molecules could be used as prognostic markers of the disease. Exosomes are small, lipid-bound vesicles able to carry various elements of the naïve cells such as proteins, lipids, mRNAs and miRNA to facilitate cell communication under normal and diseases condition. Exosomal miRNAs (exo-miRNA) have been studied in relation to many diseases. However, there is little or no knowledge regarding exo-miRNA in bronchoalveolar lavage (BAL) in IPF. Our study's aim is to evaluate the changes in the expression of two exo-miRNAs in BAL, respectively miR-21 and miR-92a, through highlighting the differences between IPF, progressive pulmonary fibrosis (PPF) and not-progressive pulmonary fibrosis (nPPF).

methodsExosomes were characterized by Western Blot and Multiplex Surface Marker Analysis. Exosomal miRNA expression was performed by qRT-PCR. ANOVA or Kruskal-Wallis test, based on data normality, was used to compare the differential expression between groups.

resultsMiR-21 expression was significantly higher in the nPPF group than in both IPF and PPF. A result that could point above a possible role of miR-21, as a biomarker in the differential diagnosis between PPF and nPPF. MiR-92a, indeed, was down regulated in PPF compared to IPF and down regulated in PPF compared to nPPF.

conclusionsThis study demonstrated the putative role of both miR-21 and miR-92a as possible biomarkers of pulmonary fibrosis progression. Moreover, the role of exo-miRNAs is examined as a possible future direction that could lead to new therapeutic strategies for the treatment of progressive and non-progressive pulmonary fibrosis.

Indexed as

Idiopathic Pulmonary FibrosisMicroRNAsBiomarkersHumansBiomarkersMicroRNAsBiomarkersExo-miRNAExosomeIPFmicroRNAProgressive pulmonary fibrosis

Identifiers

PMID37884953
PMCPMC10605223
OpenAlexW4387955608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.